

RECEIVED  
CENTRAL FAX CENTER  
JUL 13 2006

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936

#### REMARKS

##### The Claim Amendments

Applicants have canceled claim 26 and amended claims 28 and 29 to delete reference to "leukemia" and "a chemotherapeutic or anti-proliferative agent", respectively. Support may be found throughout the specification and originally-filed claims. None of these amendments adds new subject matter. Their entry is requested.

These claim amendments are made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the canceled subject matter either in this application or in other applications claiming benefit herefrom.

##### The Response

###### *Allowable Subject Matter*

Applicants acknowledge with appreciation the Examiner's indication that claims 1-24 are allowable.

###### *The Rejection Under 35 U.S.C. §112, First Paragraph*

The Examiner has rejected claims 26 and 28-29 because the Examiner, while acknowledging that the specification enables a treatment of allergic or type I hypersensitivity reaction, asthma, transplant rejection, graft versus host disease and rheumatoid arthritis, alleges that the specification does not reasonably provide enablement for the treatment of leukemia or a method of inhibiting JAK-3 in a biological sample.

Applicant has canceled claim 26 and amended claims 28 and 29 to delete reference to leukemia and an additional chemotherapeutic or anti-proliferative agent, respectively, thereby obviating this rejection.

Applicants: Randy S. Bethiel et al.  
Application No.: 10/700,936


*The Rejection Under 35 U.S.C. §112, Second Paragraph*

The Examiner has rejected claim 26<sup>1</sup> for allegedly being indefinite. Applicant has canceled claim 26, thereby obviating this rejection.

Conclusion

Applicants request that the Examiner enter the above amendments, consider the accompanying arguments, and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at his convenience.

Respectfully submitted,



Karen E. Brown  
Reg. No. 43,866  
Attorney for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6168  
Fax: (617) 444-6483

---

<sup>1</sup> The Examiner states that claim 25 is indefinite. However, claim 25 was previously canceled and it appears that the Examiner intended claim 26.